产品
编 号：F747416
分子式：C12H14N2O
分子量：202.25
分子式：C12H14N2O
分子量：202.25
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1824609-67-7
产品详情
生物活性：
Acloproxalap is a quinoline-based aldehyde scavenger that can be used in studies of diseases with toxic aldehyde accumulation, such as inflammatory diseases of the eye and skin, respiratory diseases such as pneumonia, organ diseases, and viral infection-related syndromes.
体内研究：
Acloproxalap (compound I-6) (100 or 200 mg/kg, i.p. or p.o., everyday, 6 days) can effectively improve inflammation of the colon in acute ulcerative colitis (UC) female Swiss Webster mice.Animal Model:Acute ulcerative colitis (UC) in female Swiss Webster mice
Dosage:100 mg/kg, 200 mg/kg
Administration:Intraperitoneal injection for 100 mg/kg, oral gavage for 200 mg/kg; everyday; 6 days
Result:Inhibited weight loss in intraperitoneal injection mice significantly while there was no significant difference in the oral gavage group compared to the control group.Both significantly reduced colonic histopathological parameters.
Animal Model:Male non-na?ve beagle dogs
Dosage:3 mg/kg
Administration:Intravenous injection; once
Result:The pharmacokinetic parameters of Acloproxalap (compound I-1) ParameterAcloproxalap (compound I-1)
t1/21.82 h
Tmax0.518 h
Clearance12.2 mL/kg/min
steady-state volume1385 mL/kg
AUC0-t4103 ng/mL*h
AUC0?inf_obs4137 ng/mL*h
Animal Model:Male non-na?ve beagle dogs
Dosage:10 mg/kg
Administration:Oral gavage; once
Result:The pharmacokinetic parameters of Acloproxalap (compound I-1)ParameterAcloproxalap (compound I-1)
t1/23.02 h
Tmax0.518 h
Cmax3558 ng/mL
AUC0-t9361 ng/mL*h
AUC0?inf_obs9546 ng/mL*h
BioA75%
Acloproxalap is a quinoline-based aldehyde scavenger that can be used in studies of diseases with toxic aldehyde accumulation, such as inflammatory diseases of the eye and skin, respiratory diseases such as pneumonia, organ diseases, and viral infection-related syndromes.
体内研究：
Acloproxalap (compound I-6) (100 or 200 mg/kg, i.p. or p.o., everyday, 6 days) can effectively improve inflammation of the colon in acute ulcerative colitis (UC) female Swiss Webster mice.Animal Model:Acute ulcerative colitis (UC) in female Swiss Webster mice
Dosage:100 mg/kg, 200 mg/kg
Administration:Intraperitoneal injection for 100 mg/kg, oral gavage for 200 mg/kg; everyday; 6 days
Result:Inhibited weight loss in intraperitoneal injection mice significantly while there was no significant difference in the oral gavage group compared to the control group.Both significantly reduced colonic histopathological parameters.
Animal Model:Male non-na?ve beagle dogs
Dosage:3 mg/kg
Administration:Intravenous injection; once
Result:The pharmacokinetic parameters of Acloproxalap (compound I-1) ParameterAcloproxalap (compound I-1)
t1/21.82 h
Tmax0.518 h
Clearance12.2 mL/kg/min
steady-state volume1385 mL/kg
AUC0-t4103 ng/mL*h
AUC0?inf_obs4137 ng/mL*h
Animal Model:Male non-na?ve beagle dogs
Dosage:10 mg/kg
Administration:Oral gavage; once
Result:The pharmacokinetic parameters of Acloproxalap (compound I-1)ParameterAcloproxalap (compound I-1)
t1/23.02 h
Tmax0.518 h
Cmax3558 ng/mL
AUC0-t9361 ng/mL*h
AUC0?inf_obs9546 ng/mL*h
BioA75%
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备